Anthony Aliquo - 10 Aug 2026 Form 3 Insider Report for Minerva Neurosciences, Inc. (NERV)

Reporting relationship
Chief Accounting Officer
Issuer ticker
NERV
Reported as of
10 Aug 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
20 Aug 2026, 16:38:32 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Frederick Ahlholm, Attorney-in-Fact

Key filing fact

Anthony Aliquo filed Form 3 for Minerva Neurosciences, Inc. (NERV) on 20 Aug 2026.

Key facts

  • This page summarizes Anthony Aliquo's Form 3 filing for Minerva Neurosciences, Inc. (NERV).
  • 0 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 20 Aug 2026, 16:38.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002149586 Primary reporting owner

Aliquo Anthony

Relationship
Chief Accounting Officer
Address
C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON
Signature
/s/ Frederick Ahlholm, Attorney-in-Fact
Signature date
20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NERV holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,683
Date
10 Aug 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,000
Exercise price
$27.68
Footnotes
F1
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,750
Exercise price
$6.33
Footnotes
F1
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,167
Exercise price
$3.11
Footnotes
F2
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$6.41
Footnotes
F3
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
22,000
Exercise price
$2.12
Footnotes
F4
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
300,000
Exercise price
$3.98
Footnotes
F5
NERV holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
150,000
Exercise price
$4.84
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Fully vested.

Footnote F2

The option vested 25% on December 13, 2023 and then vests or vested in equal quarterly installments over 3 years thereafter.

Footnote F3

The option vested 25% on October 4, 2024 and then vests or vested in equal quarterly installments over 3 years thereafter.

Footnote F4

The option vested 25% on December 5, 2025 and then vests or vested in equal quarterly installments over 3 years thereafter.

Footnote F5

The option vests 25% on December 22, 2026 and then in equal quarterly installments over 3 years thereafter.

Footnote F6

The option vests 25% on June 1, 2027 and then in equal quarterly installments over 3 years thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .